Split History
ETFs Holding BLPH »    BLPH Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Bellerophon Therapeutics is a clinical-stage therapeutics company focused on developing products that address unmet medical needs in the treatment of cardiopulmonary diseases. Co.'s focus is the continued development of its nitric oxide therapy for patients with or at risk of pulmonary hypertension, or PH, using its proprietary pulsatile nitric oxide delivery platform, INOpulse. Co.'s INOpulse program is an extension of the technology used in hospitals to deliver continuous-flow inhaled nitric oxide. Co. is developing its INOpulse for the treatment of patients with fibrotic interstitial lung disease at a risk for pulmonary hypertension. According to our BLPH split history records, Bellerophon Therapeutics has had 1 split.
BLPH split history picture
Bellerophon Therapeutics (BLPH) has 1 split in our BLPH split history database. The split for BLPH took place on February 10, 2020. This was a 1 for 15 reverse split, meaning for each 15 shares of BLPH owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split.

When a company such as Bellerophon Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the BLPH split history from start to finish, an original position size of 1000 shares would have turned into 66.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Bellerophon Therapeutics shares, starting with a $10,000 purchase of BLPH, presented on a split-history-adjusted basis factoring in the complete BLPH split history. BLPH split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 02/17/2015
End date: 01/31/2023
Start price/share: $138.60
End price/share: $1.94
Dividends collected/share: $0.00
Total return: -98.60%
Average Annual Total Return: -41.51%
Starting investment: $10,000.00
Ending investment: $140.03
Years: 7.96
Date Ratio
02/10/20201 for 15
BLPH is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

BLRX Split History
BLUE Split History
BMRA Split History
BMY Split History
BNTC Split History
BOLT Split History
BONE Split History
BOTA Split History
BPAX Split History
BPMX Split History

Also explore: BLPH shares outstanding history

Email EnvelopeFree BLPH Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Liminal BioSciences Inc. (LMNL)
Galway Metals Inc. (GWM.CA)
Lannett Company, Inc. (LCI)
Reed's, Inc. (REED)
Phio Pharmaceuticals Corp. (PHIO)
Swvl Holdings Corp (SWVL)
Sientra, Inc. (SIEN)
Eargo, Inc. (EAR)
Alterity Therapeutics Limited (ATHE)
Aytu BioPharma, Inc. (AYTU)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

BLPH Insider Buying

BLPH Split History | www.SplitHistory.com | Copyright © 2013 - 2023, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.